He is Head Human Immunology Program, Istituto Nazionale di Genetica Molecolare-INGM, Milan and SVP Senior research Fellow, Humabs/Vir Biotechnology,[1] Bellinzona and San Francisco (USA).

This study uncovered a critical step in the process of T-B cell cooperation that is essential for high affinity antibody production and is the basis for the development of glycoconjugate vaccines.

In 1994 Sallusto and Lanzavecchia discovered that human monocytes could be induced to differentiate in vitro into immature dendritic cells that resemble those that function as sentinels in peripheral tissues ([8]), contributing to the rapid advancement of the field in the late nineties.

Starting in 2003, the laboratory developed efficient methods to isolate human monoclonal antibodies as new tools for prophylaxis and therapy of infectious diseases ([15]).

[25] Recent highly cited work on Covid-19 analyzes the sensitivity of the virus to mRNA vaccine-elicited antibodies[26] and the receptor-binding domain of the SARS-CoV-2 Omicron variant.